Cerus Corporation (NASDAQ: CERS) recently announced that the CMS (Centers of Medicare and Medical Services) gave the company new tech add-on payments for INTERCEPT Fibrinogen Complex found in Medical Hospital IPPS (Inpatient Prospective Payment System). The company got the NTAP under an alternative CMS NTAP pathway. This route takes into account the transformative nature of goods given Breakthrough Device status by the FDA.
The NTAP for individuals getting IFC to manage excessive bleeding linked to fibrinogen deficiency is an addition to the MS-DRG (Medicare severity diagnosis-related group) assigned to individual inpatient stays. In the final rule of the IPPS, CMS has shown that the NTAP’s value will be a max of $2535 for each patient getting IFC. It’ll be triggered when the cost of care becomes more than the MS-DRG payment.
Senior Management
VP of Corporate Affairs in Cerus, Jessica Hanover, Ph.D., said that issuing an NTAP by the CMS would help support Medicare beneficiaries and make this new innovative medical product designed to treat life-threatening bleeding scenarios accessible in the inpatient system. She continued to say that they applauded CMS for deciding to grant this added payment for IFC. The need for better and more effective tools to help excessive bleeding situations is essential. When minutes, or even seconds, matter in some of the extreme cases, having access to IFC will improve the accessibility for many hospitals.
The FDA approved INTERCEPT’s Blood System for Cryoprecipitation. This is actually used to come up with the INTERCEPT Fibrinogen Complex to manage and treat excessive bleeding, which includes massive hemorrhage linked to fibrinogen deficiency. In addition, IFC was given FDA Breakthrough Device designation in November 2020. This was largely based on the potential it displayed to help treat life-threatening bleeding scenarios and massive hemorrhage.
Cerus is dedicated to safeguarding the global blood supply. The company intends to become the world’s preeminent blood products company.
